Acumen Pharmaceuticals (ABOS) Insider Porter Sells 6,460 Shares
Derrell Porter sold 6,460 shares of ABOS on June 15, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Derrell Porter sold 6,460 shares of Acumen Pharmaceuticals, Inc. ($ABOS) on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ABOS is up 2.6% after 1 week, down 5.1% after 1 month and down 27.8% to date (from the $2.34 close on Jun 15, 2026).
ABOS
Acumen Pharmaceuticals, Inc.
Key Points
- Derrell Porter sold 6,460 shares of ABOS on June 15, 2026, at an unspecified price.
- ABOS shares traded near $2.33 with peer RA Capital Management holding over 20.9 million shares worth $49.5 million.
- Analysts including BTIG and Citigroup maintain 'Buy' ratings on ABOS with price targets ranging from $4 to $11.
Get $ABOS trade alerts by text
We text you when insiders, Congress or big funds trade $ABOS. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Acumen Pharmaceuticals, Inc. alert may contain errors. Disclosures
On June 15, 2026, Derrell Porter sold 6,460 shares of ABOS. The shares were sold at an unspecified price, but ABOS shares were trading around $2.33 at the time.
What Changed in Derrell Porter's ABOS Position
Derrell Porter's recent transaction involved selling 6,460 shares of ABOS, without a set price reported for the sale. This action reflects a reduction in his holdings.
Other Institutional Activity in ABOS
RA Capital Management, L.P. increased its holdings in ABOS by 6,060,606 shares, ending with over 20.9 million shares valued at approximately $49.5 million. Sands Capital Alternatives, LLC also grew its position by 303,030 shares, now holding about 3.7 million shares worth $8.8 million. Alyeska Investment Group, L.P. significantly boosted its stake by 1,515,151 shares, bringing its total to around 2.5 million shares valued at $5.8 million. Meanwhile, Franklin Resources Inc maintained its holdings at 2.3 million shares, valued at $5.4 million.
Acumen Pharmaceuticals, Inc. Stock Down 12.1%
Shares of ABOS traded near $2.33. The stock's recent activity shows a 52-week low of $1.50 and a high of $3.50. The 50-day moving average is $2.25, while the 200-day moving average stands at $2.80.
Insider Buying and Selling at Acumen Pharmaceuticals, Inc.
Derrell Porter has been active with ABOS shares recently. On June 17, 2026, he both acquired and sold 13,040 shares at average prices of $1.07 and $2.33, respectively. On June 16, he sold 12,800 shares at $2.33, and on June 15, he sold 6,460 shares at $2.35.
Analysts Set New Price Targets
Analysts continue to show confidence in ABOS. On March 17, 2026, BTIG maintained its 'Buy' rating with an $8.00 price target. Citigroup initiated coverage with a 'Buy' rating and a $4.00 target on June 17, 2025. HC Wainwright & Co. reiterated their 'Buy' rating with a $15.00 price target back in November 2024.
About ABOS
ABOS operates within the healthcare sector, focusing on innovative treatments. The company is committed to advancing medical research and development to improve patient outcomes.
Bottom Line
Derrell Porter's recent sale of ABOS shares is a notable insider activity, although it's not uncommon for insiders to trade shares for various reasons. Institutional investors like RA Capital Management continue to show interest in ABOS, maintaining significant positions. Analysts remain optimistic, with several firms maintaining 'Buy' ratings and setting various price targets, reflecting confidence in the company's long-term potential.
Related Filing Alerts
Source: Derrell Porter's Form 4 filing on $ABOS (Jun 15, 2026). Find the original filing: ABOS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts